Related Posts
Incannex Partners with the Monash Trauma Group to assess IHL-216A in a model of sports concussion
Incannex Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
Harvest Technology Group Ltd (ASX:HTG) – R&D Tax Incentive
